PTC Therapeutics PTCT Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| —— | -$363.3M+42.0% | -$626.6M-12.1% | -$559.02M-6.7% | ||
| $38.82M-48.7% | $75.66M-68.0% | $236.59M+83.6% | $128.84M+101% | ||
| $74.55M-0.1% | $74.62M-26.6% | $101.64M-7.9% | $110.33M+6.6% | ||
| —— | -$55.91M-9.8% | -$50.91M-48.5% | -$34.28M-9,192% | ||
| $1.22M+1.8% | $1.2M-36.0% | $1.87M-1.5% | $1.9M+2.9% | ||
| $53.9M+974% | -$6.16M— | —— | $6.67M— | ||
| —— | —— | $49.43M+79.5% | $27.54M-39.7% | ||
| —— | -$107.96M-340% | $44.99M-12.8% | $51.62M+237% | ||
| —— | $11.83M— | —— | —— | ||
| —— | —— | —— | $1.35M— | ||
| —— | —— | —— | —— | ||
| $7.47M-3.7% | $7.75M-21.1% | $9.83M-0.6% | $9.88M+33.8% | ||
| —— | -$4.48M+96.5% | -$129.2M— | —— | ||
| —— | -$1.73M— | —— | $53.24M— | ||
| —— | -$107.69M+32.0% | -$158.42M+55.6% | -$356.65M-41.9% | ||
| $8.86M— | —— | $28.44M-11.2% | $32.02M+13.5% | ||
| $1.36B+124% | $607.98M+249% | $174.09M+230% | $52.76M-84.2% | ||
| $783.9M+42.6% | $549.61M— | —— | $405.23M-52.0% | ||
| $291.15M+330% | $67.75M-26.5% | $92.18M-23.5% | $120.44M+111% | ||
| —— | —— | —— | —— | ||
| -$895.99M-2,128% | $44.18M+125% | -$176.74M-161% | $290.18M+32.4% | ||
| $93.1M+226% | $28.57M+18.8% | $24.04M+64.3% | $14.63M-15.5% | ||
| —— | $18.2M— | —— | $40.4M— | ||
| $331.09M+21.1% | $273.49M-57.7% | $646.4M+285% | $167.95M+704% | ||
| —— | -$7.33M— | —— | —— | ||
| —— | $185.03M-41.1% | $314.36M+218% | $98.71M— | ||
| —— | —— | $36.13M+95.7% | $18.46M— | ||
| $18.02M+43.8% | $12.53M+470% | $2.2M+223% | -$1.79M+66.2% | ||
| $1.22M+1.8% | $1.2M-36.0% | $1.87M-1.5% | $1.9M+2.9% | ||
| —— | -$4.48M+96.5% | -$129.2M— | —— | ||
| —— | $7.69M— | —— | -$3.56M+41.5% | ||
| —— | —— | $4.38M— | —— | ||
| —— | $10.43M-26.1% | $14.11M— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | -$55.63M— | —— | ||
| $10.78M+97.2% | $5.46M— | —— | —— | ||
| —— | $99.9M— | —— | —— | ||
| —— | -$1.8M— | —— | -$9.6M— | ||
| -$2.64M— | —— | —— | —— | ||
| —— | -$107.96M-340% | $44.99M-12.8% | $51.62M+237% | ||
| $215.16M+3.7% | $207.39M+97.9% | $104.79M+44.3% | $72.64M-6.5% | ||
| $228.57M+25.9% | $181.51M+94.2% | $93.46M+91.8% | $48.74M+108% | ||
| $7.47M-3.7% | $7.75M-21.1% | $9.83M-0.6% | $9.88M+33.8% | ||
| $291.15M+330% | $67.75M-26.5% | $92.18M-23.5% | $120.44M+111% | ||
| $783.9M+42.6% | $549.61M— | —— | $405.23M-52.0% | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | -$7.33M— | —— | —— | ||
| $26.64M— | —— | —— | —— | ||
| —— | —— | $54.62M+64.3% | $33.24M+49.1% | ||
| $766K— | —— | —— | —— | ||
| —— | $150M— | —— | —— | ||
| —— | $6.46M— | —— | —— | ||
| —— | -$114.19M+38.9% | -$186.86M+51.9% | -$388.67M-39.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does PTC Therapeutics generate?
- PTC Therapeutics (PTCT) generated $704.1M in operating cash flow over the trailing twelve months.
- What is PTC Therapeutics's free cash flow?
- After $8.3M of capital expenditures, PTC Therapeutics's free cash flow was $696.9M over the trailing twelve months, up 637.5% year over year.
- Where does PTC Therapeutics's cash flow data come from?
- Every line is extracted from PTC Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
